Naohisa Uchimura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Naohisa Uchimura has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Ichiro Sora
Department of Psychiatry, Kobe University Graduate School of Medicine, Kobe, Japan
2 shared publications - Masaomi Iyo
Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan
2 shared publications - Mitsuhiko Yamada
Department of Neuropsychopharmacology, National Institute of Mental Health National Center of Neurology and Psychiatry Tokyo Japan
2 shared publications - Mitsunari Habukawa
Department of Neuropsychiatry, Kurume University School of Medicine, Kurume, Fukuoka, Japan
2 shared publications - Nakao Iwata
Fujita Health University
2 shared publications - Norio Ozaki
Department of Psychiatry, Nagoya University Graduate School of Medicine, Aichi, Japan
2 shared publications
Latest Publications
- Open Access
- 9 November 2023
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 44 (1) , 80-89
Trends in the multiple prescriptions of hypnotic drugs in a university outpatient in Japan
Aims: In Japan, the daily dosage of hypnotic drugs for insomnia treatment is increasing year by year, and over‐dependence on treatment with hypnotic drugs is a major problem. This study aimed to examine the factors related to the elimination of prescriptions of three or more hypnotic drugs within 1 year in our clinic.Methods: We conducted two surveys. Survey ① assessed the frequency of prescriptions of three or more hypnotic drugs by retrospectively reviewing the medical records of all patients who visited general and psychiatric outpatient clinics from January 2013 to March 2019. Survey ② assessed changes in prescriptions of hypnotic and psychotropic drugs within the subsequent year by retrospectively reviewing the medical records of all patients prescribed three or more hypnotic drugs who visited neuropsychiatric outpatient clinics multiple times between April 2013 and March 2019.Results: The frequency of prescribing three or more hypnotic drugs was six to nine times higher in psychiatry than in other departments. Flunitrazepam and brotizolam were the most common drugs prescribed and had the second lowest discontinuation rate after zolpidem. Conversely, eszopiclone, zopiclone, and suvorexant had the highest discontinuation rates. The success factors for drug reduction were age (odds ratio [OR]: 0.97, p < 0.0037), trazodone addition (OR: 12.86, p < 0.0194) and number of years of psychiatric experience.Conclusions: The characteristics and success factors in relation to drug reduction in patients with multiple prescriptions of hypnotic drugs identified in this study may contribute to solving the problem of multiple prescriptions of hypnotic drugs.
- 9 November 2023
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 44 (1) , 80-89
Open AccessTrends in the multiple prescriptions of hypnotic drugs in a university outpatient in Japan
Aims: In Japan, the daily dosage of hypnotic drugs for insomnia treatment is increasing year by year, and over‐dependence on treatment with hypnotic drugs is a major problem. This study aimed to examine the factors related to the elimination of prescriptions of three or more hypnotic drugs within 1 year in our clinic.Methods: We conducted two surveys. Survey ① assessed the frequency of prescriptions of three or more hypnotic drugs by retrospectively reviewing the medical records of all patients who visited general and psychiatric outpatient clinics from January 2013 to March 2019. Survey ② assessed changes in prescriptions of hypnotic and psychotropic drugs within the subsequent year by retrospectively reviewing the medical records of all patients prescribed three or more hypnotic drugs who visited neuropsychiatric outpatient clinics multiple times between April 2013 and March 2019.Results: The frequency of prescribing three or more hypnotic drugs was six to nine times higher in psychiatry than in other departments. Flunitrazepam and brotizolam were the most common drugs prescribed and had the second lowest discontinuation rate after zolpidem. Conversely, eszopiclone, zopiclone, and suvorexant had the highest discontinuation rates. The success factors for drug reduction were age (odds ratio [OR]: 0.97, p < 0.0037), trazodone addition (OR: 12.86, p < 0.0194) and number of years of psychiatric experience.Conclusions: The characteristics and success factors in relation to drug reduction in patients with multiple prescriptions of hypnotic drugs identified in this study may contribute to solving the problem of multiple prescriptions of hypnotic drugs.
- Open Access
- 25 May 2012
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 66 (4) , 261-269
State and trait markers of emotionally charged visual event‐related potentials (P300) in drug‐naïve schizophrenia
Aim: In the present study, we investigated the changes in P3 component in the emotionally charged visual event‐related potentials (ERP) in 30 drug‐naïve schizophrenic patients for up to 1 year.Methods: Visual oddball event‐related potential was recorded from six recording sites for crying baby or smiling baby photographs. ERP were recorded before the treatment (session 1 [S1]), after 3 months (session 2 [S2]), and after 12 months (session 3 [S3]), as well as in 30 healthy subjects.Results: Before taking medicine, there were no significant differences in the P300 amplitude between viewing photographs of a crying and a smiling baby. The P300 amplitude was significantly larger at S2 and S3 than at S1 for a crying baby, while there was no significant difference among sessions for a smiling baby after medication. A significant difference of the P300 amplitude was only observed between S3 and healthy subjects for a smiling baby. The P300 latency only when viewing a smiling face became significantly longer at S3 than those at S1 and S2. A significant negative correlation was obtained between the P300 amplitude changes upon viewing crying faces and negative syndrome score changes at the Pz site.Conclusion: The P300 amplitude induced by crying‐face stimuli may be a state marker and the P300 amplitude caused by smiling‐face stimuli may be a trait marker during recovery in schizophrenic patients. Atypical antipsychotic medications may be useful and may recover cognitive function reflected by the emotionally charged visual P300 components in schizophrenic patients.
- 25 May 2012
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 66 (4) , 261-269
Open AccessState and trait markers of emotionally charged visual event‐related potentials (P300) in drug‐naïve schizophrenia
Aim: In the present study, we investigated the changes in P3 component in the emotionally charged visual event‐related potentials (ERP) in 30 drug‐naïve schizophrenic patients for up to 1 year.Methods: Visual oddball event‐related potential was recorded from six recording sites for crying baby or smiling baby photographs. ERP were recorded before the treatment (session 1 [S1]), after 3 months (session 2 [S2]), and after 12 months (session 3 [S3]), as well as in 30 healthy subjects.Results: Before taking medicine, there were no significant differences in the P300 amplitude between viewing photographs of a crying and a smiling baby. The P300 amplitude was significantly larger at S2 and S3 than at S1 for a crying baby, while there was no significant difference among sessions for a smiling baby after medication. A significant difference of the P300 amplitude was only observed between S3 and healthy subjects for a smiling baby. The P300 latency only when viewing a smiling face became significantly longer at S3 than those at S1 and S2. A significant negative correlation was obtained between the P300 amplitude changes upon viewing crying faces and negative syndrome score changes at the Pz site.Conclusion: The P300 amplitude induced by crying‐face stimuli may be a state marker and the P300 amplitude caused by smiling‐face stimuli may be a trait marker during recovery in schizophrenic patients. Atypical antipsychotic medications may be useful and may recover cognitive function reflected by the emotionally charged visual P300 components in schizophrenic patients.
- Open Access
- 1 March 2011
- Published by Bentham Science Publishers Ltd. in Current Neuropharmacology
- Vol. 9 (1) , 169-175
Association Study of Serine Racemase Gene with Methamphetamine Psychosis
Experimental studies have demonstrated that not only dopaminergic signaling but also glutamatergic/NMDA receptor signaling play indispensable roles in the development of methamphetamine psychosis. Our recent genetic studies provided evidence that genetic variants of glutamate-related genes such as DTNBP1, GLYT1, and G72, which are involved in glutamate release and regulation of co-agonists for NMDA receptors, conferred susceptibility to methamphetamine psychosis. Serine racemase converts l-serine to d-serine, which is an endogenous co-agonist for NMDA receptors. Three single nucleotide polymorphisms (SNPs) in the promoter region of the serine racemase gene (SRR), rs224770, rs3760229, and rs408067, were proven to affect the transcription activity of SRR. Therefore, we examined these SNPs in 225 patients with methamphetamine psychosis and 291 age- and sex-matched controls. There was no significant association between methamphetamine psychosis and any SNP examined or between the disorder and haplotypes comprising the three SNPs. However, rs408067 was significantly associated with the prognosis for methamphetamine psychosis and multi-substance abuse status. The patients with C-positive genotypes (CC or CG) of rs408067 showed better prognosis of psychosis after therapy and less abuse of multiple substances than the patients with GG genotypes. Because the C allele of rs408067 reduces the expression of SRR, a lower d-serine level or reduced NMDA receptor activation may affect the prognosis of methamphetamine psychosis and multiple substance abuse. Our sample size is, however, not large enough to eliminate the possibility of a type I error, our findings must be confirmed by replicate studies with larger samples.
- 1 March 2011
- Published by Bentham Science Publishers Ltd. in Current Neuropharmacology
- Vol. 9 (1) , 169-175
Open AccessAssociation Study of Serine Racemase Gene with Methamphetamine Psychosis
Experimental studies have demonstrated that not only dopaminergic signaling but also glutamatergic/NMDA receptor signaling play indispensable roles in the development of methamphetamine psychosis. Our recent genetic studies provided evidence that genetic variants of glutamate-related genes such as DTNBP1, GLYT1, and G72, which are involved in glutamate release and regulation of co-agonists for NMDA receptors, conferred susceptibility to methamphetamine psychosis. Serine racemase converts l-serine to d-serine, which is an endogenous co-agonist for NMDA receptors. Three single nucleotide polymorphisms (SNPs) in the promoter region of the serine racemase gene (SRR), rs224770, rs3760229, and rs408067, were proven to affect the transcription activity of SRR. Therefore, we examined these SNPs in 225 patients with methamphetamine psychosis and 291 age- and sex-matched controls. There was no significant association between methamphetamine psychosis and any SNP examined or between the disorder and haplotypes comprising the three SNPs. However, rs408067 was significantly associated with the prognosis for methamphetamine psychosis and multi-substance abuse status. The patients with C-positive genotypes (CC or CG) of rs408067 showed better prognosis of psychosis after therapy and less abuse of multiple substances than the patients with GG genotypes. Because the C allele of rs408067 reduces the expression of SRR, a lower d-serine level or reduced NMDA receptor activation may affect the prognosis of methamphetamine psychosis and multiple substance abuse. Our sample size is, however, not large enough to eliminate the possibility of a type I error, our findings must be confirmed by replicate studies with larger samples.
- 1 August 2009
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 33 (5) , 903-905
Genetic association analysis of NRG1 with methamphetamine-induced psychosis in a Japanese population
- 1 August 2009
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 33 (5) , 903-905
Genetic association analysis of NRG1 with methamphetamine-induced psychosis in a Japanese population
- 1 January 1990
- Published by Elsevier in Neuroscience Research Supplements
- Vol. 15, S51
Effects of serotonin on nucleus accumbens neurons of the rat brain
- 1 January 1990
- Published by Elsevier in Neuroscience Research Supplements
- Vol. 15, S51
Effects of serotonin on nucleus accumbens neurons of the rat brain